Navigation Links
Enerkem GreenField Alberta Biofuels Awarded Permit to Build World's First Commercial Municipal Waste-to-Biofuels Facility
Date:5/20/2009

he biofuels facility is expected to begin by the end of 2009, at a total cost of approximately CDN$70 million. The City of Edmonton and the Province of Alberta, through the Alberta Energy Research Institute (AERI), are contributing a combined CDN$20 million to its production. Upon completion, the facility will initially produce 36 million litres (9.5 million gallons) of ethanol per year, reducing Alberta's carbon dioxide (CO2) footprint by more than 6 million tons over the next 25 years - the equivalent of removing 12,000 cars off the road every year. The plant will also contribute to meeting the Canadian and provincial 5% renewable fuel mandate.

About Enerkem GreenField Alberta Biofuels

Enerkem GreenField Alberta Biofuels (EGAB) is a limited partnership created to conduct the construction and operation of a municipal waste-to-biofuels plant using the Enerkem technology in Edmonton, Alberta.

About Enerkem

Enerkem (www.enerkem.com) is a leading waste-to-biofuels and green chemicals technology company. It has developed a unique gasification, sequential gas conditioning and catalysis technology platform capable of using a mix of feedstock such as sorted municipal solid waste, forest biomass and agricultural residues. The company is headquartered in Montreal, Quebec, and has engineering offices in Sherbrooke, Quebec. It has a pilot plant in operation since 2003 in Sherbrooke, Quebec. Enerkem's first commercial-scale plant is based in Westbury, Quebec. The company is also involved in the development of a municipal waste-to-biofuels plant in Edmonton, Alberta, and recently announced the development of a second-generation biofuels production facility to be located in Pontotoc, Mississippi. Enerkem is a private company financed by leading US venture capital firms Rho Ventures and Braemar Energy Ventures, the Canadian investment fund BDR Capital and the Comp
'/>"/>

SOURCE Enerkem Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi
2. Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase
3. Enerkem Expands Executive Management Team
4. GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality
5. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
6. BioMS Medical to present at Alberta Economic Forum in Geneva
7. University of Alberta and NINT researchers make solar energy breakthrough
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
10. DuPont Statement on Obama Administration Biofuels Interagency Working Group
11. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... 19 New long-term data from two pivotal, Phase ... arthritis (RA) receiving SIMPONI (TM) (golimumab) every four ... physical function response through one year. These new ... of Rheumatology (ACR) Annual Scientific Meeting. , "New data ...
... , QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna ... (the "Company"), a global biopharmaceutical company focused on ... has initiated activities intended to complete the clinical ... ghrelin agonist compound macimorelin (AEZS-130) which could be ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
Cached Biology Technology:New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 2New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 3New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 4New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 5New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 6New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 7New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 8New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 9New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 10AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... births resulting from in-vitro-fertilization (IVF), researchers at Yale School ... that estimates the reproductive potential of individual embryos, possibly ... higher success rate in women undergoing IVF. , Over ... the United States. In 2002, 3.1 embryos on average ...
... approach can kill bacteria in laboratory experiments and eliminate ... bacterial nutrient, according to research led by a University ... UW, the University of Iowa, and the University of ... of the Journal of Clinical Investigation. , Bacteria ...
... of light are providing insight into the complexities of the ... of how the human brain works. , Investigators at Duke ... engineered a strain of mice whose olfactory brain cells "fire" ... the cells a gene naturally present in green algae that ...
Cached Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
... family of calcium binding proteins such as calmodulin ... an alpha and beta chain whereas S100B is ... is also expressed in the antigen presenting cells ... interdigitating reticulum cells in the paracortex of lymph ...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Polyclonal Antibody to AHI1 / Jouberin...
Biology Products: